Paradoxical skin lesions induced by IL-17 inhibitors in SAPHO syndrome

Figures & data

Figure 1. (A–G) The paradoxical skin lesions of the 7 cases with SAPHO syndrome treated with IL-17A inhibitors. (Ai) After discontinuing IL-17A inhibitors and adding tofacitinib for 10 weeks, the paradoxical skin lesions has improved. (Bi) After discontinuing IL-17A inhibitors and adding tofacitinib for 2 weeks, the paradoxical skin lesions has improved. (Ci) After discontinuing IL-17A inhibitors and adding tofacitinib for 2 weeks, the paradoxical skin lesions has improved. (Di) After discontinuing IL-17A inhibitors and adding tofacitinib for 12 weeks, the paradoxical skin lesions has improved. (Ei) After discontinuing IL-17A inhibitors and adding tofacitinib for 8 weeks, the paradoxical skin lesions has improved. (Fi) After discontinuing IL-17A inhibitors and adding tofacitinib for 5 weeks, the paradoxical skin lesions has improved. (Gi) After discontinuing IL-17A inhibitors and adding tofacitinib for 6 weeks, the paradoxical skin lesions has improved.

Table 1. Patient and skin eruption characteristics.

Pt	Sex	Age(yrs)	Anti-IL17A agent	Duration of therapy (weeks)	Joint pain symptoms improved	PPP improved	Clinical aspects	Discontinuation of treatment	Management	Time to remisssion (weeks)
1	F	39	Secukinumab	2	No	No	PPP aggravated, nail damage.	Yes	Tofacitinib	10
2	M	58	Secukinumab	4	Yes	No	Sterile pimples eruption.	Yes	Tofacitinib	2
3	F	54	Secukinumab	3	No	No	Sterile pimples eruption.	Yes	Tofacitinib	2
4	M	43	Secukinumab	3	No	No	PPP aggravated.	Yes	Tofacitinib	12
5	M	50	Secukinumab	4	Yes	No	PPP aggravated.	Yes	Tofacitinib	8
6	F	31	Secukinumab	2	Yes	No	PPP aggravated, alopecia areata.	Yes	Tofacitinib	5
7	F	37	Secukinumab	4	No	No	PPP aggravated, new developed sterile pimples.	Yes	Tofacitinib	6

F: female; M: male; PPP: Palmarplantar pustulosis.

Data availability statement

The datasets analyzed for this study are available from the corresponding author Dr. Chen Li ([email protected]) upon reasonable request.